A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-1006 in Japanese Subject With Type 2 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2014
At a glance
- Drugs MK 1006 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck & Co
- 17 Dec 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.